Detalhe da pesquisa
1.
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Clin Genitourin Cancer
; 21(6): 643-652, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635052
2.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Clin Genitourin Cancer
; 20(5): 488-494, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977881
3.
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Eur Urol Oncol
; 1(6): 467-475, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31158090
4.
Sequential therapy in renal cell carcinoma.
Cancer
; 115(10 Suppl): 2321-6, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19402067